There is a need for continued therapeutic development based on multi-targeted therapy against the bone microenvironment. Metastatic cancer in the skeleton is the result of a complex interplay between the cancer cells themselves and the bone microenvironment resulting in a heterogeneous disease that induces a combination of osteolytic and osteoblastic lesions. The pathogenesis of bone metastases includes interactions between the cancer cells and osteoclasts, osteoblasts, endothelial cells, stromal cells, hematopoietic progenitor cells, cells of the immune system, and the bone matrix. A paradigm shift from an initial treatment strategy that primarily targets the tumor cell directly, i.e. traditional chemotherapy, to new therapies that exploit the interactions and contributions of the various cells and elements of surrounding microenvironment to the development of the metastatic lesions is now being explored and already exploited to improve the lives of cancer patients living with skeletal metastases.
|Original language||English (US)|
|Title of host publication||Bone Cancer|
|Number of pages||8|
|State||Published - Dec 1 2010|
ASJC Scopus subject areas